Related Experiment Videos
[Dyslipidemias and coronary disease]
Annales De Biologie Clinique
|January 1, 1986
Summary
Primary hyperlipoproteinemias, like familial hypercholesterolemia, strongly promote atherosclerosis. Measuring apoproteins like apo B100 aids in predicting coronary artery disease risk and guides hypocholesterolemia treatment.
Area of Science:
- Cardiovascular Genetics
- Lipid Metabolism
- Atherosclerosis Research
Context:
- Genetic hyperlipoproteinemias, particularly Fredrickson's types II and III, are strongly linked to atherosclerosis.
- Epidemiological studies confirm a significant positive correlation between cholesterol levels and coronary artery disease across diverse populations.
Purpose:
- To highlight the atherogenic role of specific primary hyperlipoproteinemias.
- To emphasize the predictive value of plasma apoprotein concentrations (apo B100, apo A-I, apo E) for coronary artery disease.
- To underscore the therapeutic importance of diagnosing and treating hypercholesterolemia for cardiovascular disease prevention.
Summary:
- Low-density lipoproteins (LDL) are highly atherogenic due to impaired recognition between apoprotein B100 (apo B100) and cellular receptors.
- Plasma apoprotein measurements are emerging as valuable biomarkers for assessing coronary artery disease risk.
- Genetic polymorphism studies may further elucidate the complex relationship between plasma lipids and atherosclerosis.
Impact:
- Establishes the critical link between genetic lipid disorders and atherosclerosis.
- Validates apolipoproteins as key indicators in cardiovascular risk assessment.
- Reinforces the clinical significance of managing hypercholesterolemia to prevent coronary artery disease.